Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers)
Publication
, Conference
Lee, MS; Parikh, AR; Spigel, DR; Dayyani, F; Spira, AI; Atreya, CE; Ulahannan, SV; Strickler, JH; Fakih, M; Grierson, P; Christenson, E; Li, Z ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2023
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Lee, M. S., Parikh, A. R., Spigel, D. R., Dayyani, F., Spira, A. I., Atreya, C. E., … Chiorean, E. G. (2023). Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).
Lee, Michael Sangmin, Aparna Raj Parikh, David R. Spigel, Farshid Dayyani, Alexander I. Spira, Chloe Evelyn Atreya, Susanna Varkey Ulahannan, et al. “Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
Lee MS, Parikh AR, Spigel DR, Dayyani F, Spira AI, Atreya CE, et al. Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers). In: JOURNAL OF CLINICAL ONCOLOGY. 2023.
Lee, Michael Sangmin, et al. “Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.
Lee MS, Parikh AR, Spigel DR, Dayyani F, Spira AI, Atreya CE, Ulahannan SV, Strickler JH, Fakih M, Grierson P, Christenson E, Outlaw DA, Khan G, Kopetz S, Bullock AJ, Li Z, Chen X, Patel H, Hazra S, Chiorean EG. Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers). JOURNAL OF CLINICAL ONCOLOGY. 2023.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences